Here's why Bristol Myers quarter wasn't enough to change our view on the stock
- Posted on October 30, 2025
- By CNBC
- 5 Views
Here's why Bristol Myers quarter wasn't enough to change our view on the stock
The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug.
